EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal: sources

EU antitrust regulators will open an extensive probe into Zimmer's (ZMH.N) $13.4 billion bid for Biomet, concerned that the creation of the world's second-largest orthopedic products group may hurt competition, three people familiar with the matter said on Thursday.

Read Full Article

Biomet Inc. improves its performance this quarter

Biomet improved financial performance this quarter, CEO tries to prove skeptics wrong.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics